260 related articles for article (PubMed ID: 18279756)
1. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M
Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756
[TBL] [Abstract][Full Text] [Related]
2. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
Biggar WD; Harris VA; Eliasoph L; Alman B
Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
[TBL] [Abstract][Full Text] [Related]
4. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
[TBL] [Abstract][Full Text] [Related]
5. Deflazacort treatment of Duchenne muscular dystrophy.
Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
[TBL] [Abstract][Full Text] [Related]
6. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
Mayo AL; Craven BC; McAdam LC; Biggar WD
Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
8. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
[TBL] [Abstract][Full Text] [Related]
9. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
Alman BA; Raza SN; Biggar WD
J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
[TBL] [Abstract][Full Text] [Related]
10. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam LC; Mayo AL; Alman BA; Biggar WD
Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
[TBL] [Abstract][Full Text] [Related]
11. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up.
Lebel DE; Corston JA; McAdam LC; Biggar WD; Alman BA
J Bone Joint Surg Am; 2013 Jun; 95(12):1057-61. PubMed ID: 23783200
[TBL] [Abstract][Full Text] [Related]
15. [Pain, osteopenia and body composition of 22 patients with Duchenne muscular dystrophy: a descriptive study].
Douvillez B; Braillon P; Hodgkinson I; Berard C
Ann Readapt Med Phys; 2005 Nov; 48(8):616-22. PubMed ID: 16023755
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density and fractures in boys with Duchenne muscular dystrophy.
Larson CM; Henderson RC
J Pediatr Orthop; 2000; 20(1):71-4. PubMed ID: 10641693
[TBL] [Abstract][Full Text] [Related]
17. Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy.
Dooley JM; Gordon KE; MacSween JM
Pediatr Neurol; 2010 Sep; 43(3):173-6. PubMed ID: 20691938
[TBL] [Abstract][Full Text] [Related]
18. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
[TBL] [Abstract][Full Text] [Related]
19. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
[TBL] [Abstract][Full Text] [Related]
20. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
Dooley JM; Bobbitt SA; Cummings EA
Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
